Orvinols with mixed kappa/mu opioid receptor agonist activity.

Benjamin M Greedy, Faye Bradbury, Mark P Thomas, Konstantinos Grivas, Gerta Cami-Kobeci, Ashley Archambeau, Kelly Bosse, Mary J Clark, Mario Aceto, John W Lewis, John R Traynor, Stephen M Husbands

Journal of medicinal chemistry 2013 Apr 25

filter terms:

Dual-acting kappa opioid receptor (KOR) agonist and mu opioid receptor (MOR) partial agonist ligands have been put forward as potential treatment agents for cocaine and other psychostimulant abuse. Members of the orvinol series of ligands are known for their high binding affinity to both KOR and MOR, but efficacy at the individual receptors has not been thoroughly evaluated. In this study, it is shown that a predictive model for efficacy at KOR can be derived, with efficacy being controlled by the length of the group attached to C20 and by the introduction of branching into the side chain. In vivo evaluation of two ligands with the desired in vitro profile confirms both display KOR, and to a lesser extent MOR, activity in an analgesic assay suggesting that, in this series, in vitro measures of efficacy using the [(35)S]GTPγS assay are predictive of the in vivo profile.

Citation

Benjamin M Greedy, Faye Bradbury, Mark P Thomas, Konstantinos Grivas, Gerta Cami-Kobeci, Ashley Archambeau, Kelly Bosse, Mary J Clark, Mario Aceto, John W Lewis, John R Traynor, Stephen M Husbands. Orvinols with mixed kappa/mu opioid receptor agonist activity. Journal of medicinal chemistry. 2013 Apr 25;56(8):3207-16